Skip to content

Case of the week 49/2019

Combined application of CytoSorb and CRRT in a patient with acute renal failure and septic shock as a consequence of lower respiratory tract infection

Dr. Ajay Gupta
Max Super Specialty Hospital, Shalimar Bagh, India

This case reports on a 57-year-old female patient, who was transferred from a peripheral hospital to the emergency department of Max Super Specialty Hospital, Shalimar Bagh, with complaints of abdominal pain, breathlessness and fever over the previous 2 days.

The Therapy

An extracorporeal blood purification method to reduce excess inflammatory mediators and elevated levels of bilirubin and myoglobin.

Fields of application

Septical shock in intensive care, vasoplegic shock in non-infectious triggers (e.g., in cardiac surgery patients), liver failure, rhabdomyolysis.

The Studies

Current multi and single center studies in Europe and USA, an international register, case series.

The Adsorber

The innovative bead technology is the core of CytoSorb, the first and only 24-hour-licensed extracorporeal cytokine adsorber.

CytoSorb register

Play Video

For the first time, treatment data, courses and results of a new therapy are systematically recorded according to high scientific standards.

Updates

The CytoSorb whole blood adsorber is a CE approved medical device for the extracorporeal removal of cytokines. The aim is to reduce excessive cytokine levels and other inflammatory mediators, while maintaining the physiological immune response. In addition, the removal of elevated levels of bilirubin and myoglobin by the adsorber has been confirmed.

It has also been observed that other hydrophobic substances of medium molecular size, such as free hemoglobin and various bacterial enterotoxins, can also be effectively removed.

CytoSorb consists of innovative porous polymer beads. This unique adsorbing technology offers the highest biocompatibility and hemocompatibility according to ISO 10993. The enormous total surface area of ​​45,000 m² per cartridge enables a highly effective elimination.

The CytoSorb treatment is intended for use in clinical situations with elevated levels of cytokine and / or bilirubin and / or myoglobin. Excessive inflammatory states are attenuated and the immune response modulated.

CytoSorb therapy is used in patients with various types of hyperinflammatory and infectious conditions such as, in particular, septic shock and systemic hyperinflammation during or after cardiopulmonary bypass in cardiac surgery (e.g., endocarditis, aortic aneurysm). Other potential indications include trauma, burns, pancreatitis, necrotizing fasciitis, combination with ECMO, liver failure and rhabdomyolysis.

In particular, haemodynamic stabilization, reduction of capillary leakage, reversal of fluid balance, improvement of organ functions as well as prevention and limitation of organ failure can be observed as therapeutic effects. REGAIN CONTROL!

The CytoSorb adsorber is a standard whole blood cartridge that is compatible with either standard clinical renal replacement therapy (CRRT), such as continuous dialysis and hemofiltration, or with heart-lung machines, or can be used as a stand-alone therapy.

The system can be set up in minutes and easily integrated into existing extracorporeal circuits without additional accessories. Safely performing CytoSorb therapy is possible with both heparin and citrate anticoagulation.

Patients can benefit from CytoSorb use in both intensive therapeutic interventions and preventive use during cardiopulmonary bypass during cardiac surgery.

To date, more than 73,000 individual applications have been performed in more than 800 clinical settings worldwide, with the treatment being well tolerated and safe.

The introduction of a new extracorporeal therapy in critical care requires maximum effort in the medical-scientific arena in order to quickly establish evidence of safety and efficacy, but also extensive knowledge regarding potential additional effects, such as interactions with established therapies. CytoSorbents is continuously working on this.

In addition to various multicenter study projects in Europe and the USA, for which we act as a sponsor, we work closely with renowned international study partners in a variety of multi- and mono-centric projects to make the use of the CytoSorb therapy even more effective and targeted.

Moreover, a large international registry, managed at the highest scientific level will systematically provide important insights into safety and effects of the therapy in the clinical routine.

Help us direct you to the right information by selecting the option that best describes you:

You are trying to enter content on the international website of CytoSorbents Europe with a US IP address.

* I am aware that the content provided on this website is in accordance with the European CE label of CytoSorb and that the CytoSorb device has neither been cleared or approved by the FDA.

You are trying to enter our US website with a non-US IP address.

This website is only for healthcare professionals in the USA.

* I am aware that the content provided on this website is in accordance with the Emergency Use Authorization (EUA) for use in critically-ill COVID-19 patients with imminent or confirmed respiratory failure, in defined circumstances, issued by the American FDA and that this EUA differs from the CE label.

You are trying to enter our international website with a US IP address.

This website is only for healthcare professionals outside the USA.

* I am aware that the content provided on this website is in accordance with the European CE label of CytoSorb and that the CytoSorb device has neither been cleared or approved by the FDA.

This website is only for healthcare professionals outside the USA.

Help us direct you to the right information by selecting the option that best describes you: